Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Zlatar, Jelena (57826101100)"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2
    (2022)
    Peric, Stojan (35750481700)
    ;
    Zlatar, Jelena (57826101100)
    ;
    Nikolic, Luka (57825768600)
    ;
    Ivanovic, Vukan (57211858030)
    ;
    Pesovic, Jovan (15725996300)
    ;
    Petrovic Djordjevic, Ivana (57815873500)
    ;
    Sreckovic, Svetlana (55979299300)
    ;
    Savic-Pavicevic, Dusanka (57212301497)
    ;
    Meola, Giovanni (7005543642)
    ;
    Rakocevic-Stojanovic, Vidosava (6603893359)
    Introduction: Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs). Aim: The aim of this study is to analyze the frequency and type of AIDs in patients with DM2 from the Serbian DM registry. Patients and Methods: A total of 131 patients with DM2 from 108 families were included, [62.6% women, mean age at DM2 onset 40.4 (with standard deviation 13) years, age at entering the registry 52 (12.8) years, and age at analysis 58.4 (12.8) years]. Data were obtained from Akhenaten, the Serbian registry for DM, and through the hospital electronic data system. Results: Upon entering the registry, 35 (26.7%) of the 131 patients with DM2 had AIDs including Hashimoto thyroiditis (18.1%), rheumatoid arthritis, diabetes mellitus type 1, systemic lupus, Sjogren's disease, localized scleroderma, psoriasis, celiac disease, Graves's disease, neuromyelitis optica, myasthenia gravis, and Guillain-Barre syndrome. At the time of data analysis, one additional patient developed new AIDs, so eventually, 36 (28.8%) of 125 DM2 survivors had AIDs. Antinuclear antibodies (ANAs) were found in 14 (10.7%) of 63 tested patients, including 12 without defined corresponding AID (all in low titers, 1:40 to 1:160). Antineutrophil cytoplasmic antibodies (ANCAs) were negative in all 50 tested cases. The percentage of women was significantly higher among patients with AIDs (82.9% vs. 55.2%, p <0.01). Conclusion: AIDs were present in as high as 30% of the patients with DM2. Thus, screening for AIDs in DM2 seems reasonable. Presence of AIDs and/or ANAs may lead to under-diagnosis of DM2. Copyright © 2022 Peric, Zlatar, Nikolic, Ivanovic, Pesovic, Petrovic Djordjevic, Sreckovic, Savic-Pavicevic, Meola and Rakocevic-Stojanovic.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2
    (2022)
    Peric, Stojan (35750481700)
    ;
    Zlatar, Jelena (57826101100)
    ;
    Nikolic, Luka (57825768600)
    ;
    Ivanovic, Vukan (57211858030)
    ;
    Pesovic, Jovan (15725996300)
    ;
    Petrovic Djordjevic, Ivana (57815873500)
    ;
    Sreckovic, Svetlana (55979299300)
    ;
    Savic-Pavicevic, Dusanka (57212301497)
    ;
    Meola, Giovanni (7005543642)
    ;
    Rakocevic-Stojanovic, Vidosava (6603893359)
    Introduction: Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs). Aim: The aim of this study is to analyze the frequency and type of AIDs in patients with DM2 from the Serbian DM registry. Patients and Methods: A total of 131 patients with DM2 from 108 families were included, [62.6% women, mean age at DM2 onset 40.4 (with standard deviation 13) years, age at entering the registry 52 (12.8) years, and age at analysis 58.4 (12.8) years]. Data were obtained from Akhenaten, the Serbian registry for DM, and through the hospital electronic data system. Results: Upon entering the registry, 35 (26.7%) of the 131 patients with DM2 had AIDs including Hashimoto thyroiditis (18.1%), rheumatoid arthritis, diabetes mellitus type 1, systemic lupus, Sjogren's disease, localized scleroderma, psoriasis, celiac disease, Graves's disease, neuromyelitis optica, myasthenia gravis, and Guillain-Barre syndrome. At the time of data analysis, one additional patient developed new AIDs, so eventually, 36 (28.8%) of 125 DM2 survivors had AIDs. Antinuclear antibodies (ANAs) were found in 14 (10.7%) of 63 tested patients, including 12 without defined corresponding AID (all in low titers, 1:40 to 1:160). Antineutrophil cytoplasmic antibodies (ANCAs) were negative in all 50 tested cases. The percentage of women was significantly higher among patients with AIDs (82.9% vs. 55.2%, p <0.01). Conclusion: AIDs were present in as high as 30% of the patients with DM2. Thus, screening for AIDs in DM2 seems reasonable. Presence of AIDs and/or ANAs may lead to under-diagnosis of DM2. Copyright © 2022 Peric, Zlatar, Nikolic, Ivanovic, Pesovic, Petrovic Djordjevic, Sreckovic, Savic-Pavicevic, Meola and Rakocevic-Stojanovic.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback